F FRESENIUS



Company Presentation

September 2022


Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Agenda









Ever better medicine for ever more people

We improve people's lives by providing high quality and affordable healthcare



A Global Leader in Health Care Products and Services



in sales (FY/2021)

Long-term opportunities in **growing**, non-cyclical markets



Global presence in **100+** countries





Strong financial performance and cash flow generation



Employees worldwide (as of June 30, 2022)



300,000+

Investment Highlights



Diversified healthcare Group with four strong business segments





Resilient business model

based on megatrends healthcare and demographics






Strong financial performance and cash flow generation




Global Trends offer Growth Opportunities for Fresenius





The Fresenius Strategy





Environment, Social and Governance: Core Priorities

Well-being of the patient

- → Access to healthcare and medicine
- → Patient & Product safety



Digital Transformation & Innovation

- → Digitalization & Innovation
- → Cybersecurity



Employees

- → Working conditions, recruitment & employee participation
- → Employee development
- → Occupational health & safety



Diversity

→ Diversity and equal opportunities



Compliance & Integrity

- → Compliance
- → Data protection
- → Human Rights
- → Supply Chain



Environment

- → Water management
- → Waste and recycling management
- → Climate protection





Fresenius Group: Significant progress on our ESG agenda



Rating and reporting progress



Ratings confirmed: CDP Climate at "B" and MSCI at "BBB". Sustainalytics at "Low Risk" (19.7)

EU Taxonomy: 1% revenue, 49% capex, and 0% Opex is **taxonomy**eligible




Employee engagement



Group-wide survey to be conducted to better understand employees' concerns and demands

Consolidated results expected in Q4/2022



Performance measurement



ESG targets program on track: KPIs defined, 15% of **Management's short-term** incentive linked to ESG

Strategy and KPI alignment to be continued in 2022

KPIs to be included in **new 2023 Long-Term Incentive Plan**




Fresenius Group: Climate Targets - our Roadmap to Climate Neutrality in 2040



Our scope 1 and 2 targets are in line with a science-based 1.5°C scenario



Continuous assessment of scope 3 emission impacts for inclusion in our targets




First priority: Transition to renewable electricity



ESG Rating Overview

We aim for continuous improvement through reporting and engagement



THE USE BY FRESENIUS SE & CO. KGAA OF ANY MSCI ESG RESEARCH LLC OR ITS AFFILIATES ("MSCI") DATA, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT, RECOMMENDATION, OR PROMOTION OF FRESENIUS SE & CO. KGAA BY MSCI. MSCI SERVICES AND DATA ARE THE PROPERTY OF MSCI OR ITS INFORMATION PROVIDERS, AND ARE PROVIDED 'AS-IS' AND WITHOUT WARRANTY. MSCI NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI.

Copyright ©2022 Sustainalytics. All rights reserved.

This publication contains information developed by Sustainalytics (www.sustainalytics.com). Such information and data are proprietary of Sustainalytics and/or its third party suppliers (Third Party Data) and are provided for informational purposes only. They do not constitute an endorsement of any product or project, nor an investment advice and are not warranted to be complete, timely, accurate or suitable for a particular purpose. Their use is subject to conditions available at https://www.sustainalytics.com/legal-disclaimers.




Fresenius Group: Global Sales Base in Growing, Non-Cyclical Markets

2021 Sales by Region



Sales in € bn





Before special items 2017-2018 excluding IFRS 16




Fresenius Group: Track Record of Healthy Organic Sales Growth

FRESENIUS














Fresenius Group: Strong and Balanced Healthcare Portfolio





Ownership: ~32%

Health Care Products Health Care Services

- Dialysis services
- · Products for hemodialysis and peritoneal dialysis
- Critical care solutions
- · Complementary assets to establish holistic treatment approach

Sales 2021: €17.6 bn





Ownership: 100%

Hospital Supplies

- IV drugs
- · Clinical nutrition
- Infusion therapy
- Medical devices/ transfusion technology
- Biosimilars

Sales 2021: €7.2 bn





Ownership: 100%

Hospital Operation

- Acute care
- Outpatient services
- Occupational risk prevention
- Fertility services

Sales 2021: €10.9 bn





Ownership: 77%

Services and Projects for Hospitals

- Post-acute care
- Project development and planning
- Turnkey construction
- · Maintenance, technical and total operational management

Sales 2021: €2.3 bn

Fresenius Group: All Fresenius segments with excellent market positions and ample growth opportunities; access to sufficient capital remains key to accelerate growth







Fresenius Group: Unlocking value by defining new strategic imperatives to execute on accelerated profitable growth

Advantages of current set-up for our stakeholders



- Diversification and size offer stability, economies of scale and tax savings
- Worldwide presence and brand reputation
- Attractive debt financing conditions

Constraints on accelerating growth



- Extensive growth capital deployment to capture incremental growth opportunities in all segments
- Fresenius financing capacity drives need to prioritize
- Fresenius equity issuance unattractive at current valuation

New strategic imperatives

















Fresenius Medical Care: Global Dialysis Market Leader

- The world's leading provider of dialysis products and services treating ~345,000 patients¹ in >4,100 clinics¹
- Provide care and products of highest quality
- Leveraging core competencies to address global healthcare challenges and further expand in the Renal Care Continuum and beyond
- Advancing global transformation program FME25 to enable further sustainable profitable growth and execution on strategy



Health care products



Health care services



Critical care solutions



Complementary assets

Sales by Region



Sales by Products and Services



Market Dynamics

Increase in global demand

>1.6 million p.a.

patients worldwide will need continuous renal replacement therapy to treat acute kidney failure in 2030

Home dialysis

By 2025, the Company aims to perform 25% of all treatments in the U.S. in a home setting

Digitalization is driving new treatment models

Leverage ever larger data sets from ~53 million dialysis treatments per year (2021) to further improve and personalize treatments




¹ As of June 30, 2022

Fresenius Kabi: A Leading Global Hospital Supplier

- Comprehensive product portfolio for critically and chronically ill patients
- Leading market positions
- Development of biosimilars with a focus on oncology and autoimmune diseases
- Vision 2026 framework initiated to increase global competitiveness and advance organizational effectiveness









Market Dynamics

Growing healthcare spending in emerging markets

+6.3% p.a. growth over the next decade

Expected market growth of biosimilars 2021 to 2028

+27% average growth p.a. in the U.S.

Rising cost consciousness in healthcare spending/significant savings from generics

~ US\$313 bn

savings p.a. in the U.S.



Fresenius Helios: Europe's Largest Private Hospital Operator

38%

- Market leader in size and quality with excellent growth prospects
- ~6%¹ share in German acute care hospital ~12%¹ share in Spanish private hospital market
- Quality is key: defined quality targets, publication of medical treatment results, peer review processes
- Development of new business models to foster digitalization and profit from trend towards outpatient treatments



Acute care



Outpatient



Occupational risk prevention



Fertility services



Market Dynamics

Hospital market in Germany ~ €111 bn

Downloads of e-health apps in Germany increased in 2020 to

2 million.

As a result of the COVID-19 pandemic, they doubles compared to the previous year.

Private hospital market in Spain

~ €16 bn

Average increase of private health insurance policies in Spain of

~2.5% p.a.



¹ Based on sales

Fresenius Vamed: Leading Global Hospital Services and Projects Specialist

- Manages hospital construction/expansion projects and provides services for healthcare facilities worldwide
- Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
- Strong track record: More than 1,000 projects in 98 countries completed
- Leading post-acute care provider in central Europe



Services



Projects



Post-acute care

Sales by Region



Sales by Service and Project Business



Market Dynamics

Telemedicine market in Europe is estimated to grow

19.1% p.a.

from 2020 to 2026.

Global preventive healthcare is estimated to grow

9.5% p.a.

till 2025.

Outsourcing of non-medical services provided by public institutions to private providers grew in Germany by

40%


from 2014 to 2019.

Emerging markets' share of global health expenditure will grow to

33% by 2022.



Medium-term Growth Targets 2020 – 2023 (CAGRs): Sales target specified whilst temporary headwinds weigh on net income development




Acquisitions have smaller contributions than the $\sim 1\%$ additional growth originally expected



Before special items



Fresenius SE: Earnings-Linked Dividend Policy



Track record

29th consecutive dividend increase

CAGR dividend increase

+14%

Dividend Policy

Dividend growth aligned to EPS¹ growth

Pay-out Ratio:

~ 20% to 25%

¹ Before special items




Fresenius SE: Fresenius Share & Shareholder Structure


Share price development LTM



Click to view our interactive share price tool




Shareholder structure by investors




Analyst recommendations




Click to view downloadable set of the consensus data



Shareholder structure by region



Fresenius SE: Historical Share Price Performance






Agenda









Key messages Q2 2022



Weak Q2 amid intensifying U.S. labor shortages and accelerating macro-economic challenges



FY/22 Group guidance driven by Fresenius Medical Care's outlook adjustment



Medium-term targets: Sales CAGR specified; net income¹ CAGR no longer believed to be achievable



"Meet the Management" with Fresenius Kabi on October 7, 2022



Marked by increased headwinds from U.S. labor market and global inflation



In line with expectations; biosimilars business progressing well



Solid organic growth in Germany and Spain based on healthy activity levels



Supply chain disruptions and higher material costs remain headwinds

¹ Net income attributable to shareholders of Fresenius SE&Co. KGaA; before special items



Fresenius Kabi: Solid Q2/22 on tough comps; acquisition of majority stake in mAbxience closed; biosimilar business progressing well



North America

Solid quarter with market share gains despite supply disruptions, staff shortages and inflationary headwinds

Price pressure eased; low single-digit price erosion in our base product portfolio in Q2/22

GPO tendering in line with expectations; new price scheme to be implemented in Q3/22

FDA inspected Melrose Park facility - feedback expected in Q3/22



Ivenix

Integration of business is **progressing well**

Large volume pump including infusion management software tool receiving promising customer feedback

Asia-Pacific

China marked by significant NVBP related price pressure

APAC ex China with good business performance in Q2/22



Biosimilars

Acquisition of majority stake in mAbxience closed

Clinical programs for further molecules of Kabi's portfolio progressing according to plan

Biologics License Application (BLA) for tocilizumab accepted for review by FDA



01 Business Update

Fresenius Helios: Continued healthy activity levels in Germany and Spain; limited impact from cost inflation; Fertility business progressing well



Helios Germany



Solid admissions growth sequentially (+4%) and Q2 year-over-year (+5%)

Patients returning to hospitals for elective treatments, COVID-19 no longer seen as hurdle

Sufficient bed capacity available despite rising number of Omicron patients



Helios Spain



Ongoing growing activity levels in Spain and Latin America

Omicron wave in O2: Moderate impact from related temporary local staff shortages

Acquisition of two small medical centers near Barcelona and Zaragoza; hospital **expansions** in Madrid and Málaga completed; opening of new health center in Madrid

Ouirónsalud ranked¹ amongst **TOP 30** most reputed companies in Spain, #1 in healthcare



Helios Fertility

Activity picking up during Q2 due to receding COVID-related impact

Acquisition of two facilities in Brazil and one in the U.S. (North Carolina)

Further **bolt-on acquisitions** expected in FY/22

¹ Merco Corporate Reputation Business Monitor, Spain, 2022



Fresenius Vamed: Macro challenges remain a headwind in the project business; service business shows continuing good performance



Macro challenges

 Supply chain disruptions and higher material costs weigh on project business in Q2/22

Service business - good performance

- Rehabilitation business supported by ongoing good activity levels
- Continued strong contribution from high-end services

Project business - order intake remains at a high level

- Sales in project business decreased by 12% in Q2/22 over a strong prior year
- Order backlog at all-time high €3.73bn


Major turnkey contract in Q2/22:

Turnkey Project, Regional Hospitals in Angola




Agenda









Q2/22 Profit and Loss Statement

Sales

+3%

Q2/22: €10,018 m

Net Interest

-€116 m

Q2/21: -€121 m

EBIT

-9%

Q2/22: €1,003 m

Income Tax Rate


23.0%

Q2/21: 21.5%



All growth rates in constant currency (cc) Before special items ¹ Excluding Ivenix acquisition Net income attributable to shareholders of Fresenius SE & Co. KGaA

Q2/22 Business Segment Growth



All figures before special items

¹ Excluding Ivenix acquisition

For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.



Q2/22 Cash Flow


	Operating CF		Capex (net)		Free Cash Flow ¹	
€m	Q2/2022	LTM Margin	Q2/2022	LTM Margin	Q2/2022	LTM Margin
FRESENIUS MEDICAL CARE	751	12.3%	-169	-4.2%	582	8.1%
FRESENIUS KABI	109	13.1%	-110	-6.8%	-1	6.3%
FRESENIUS HELIOS	194	7.3%	-146	-5.1%	48	2.2%
FRESENIUS VAMED	7	4.2%	-9	-2.1%	-2	2.1%
Corporate/Other	-44	n.a.	-2	n.a.	-46	n.a.
F FRESENIUS Excl. FMC ²	393	9.4%	-267	-5.4%	126	4.0%
F FRESENIUS	1,017	10.5%	-436	-4.9%	581	5.6%

Before acquisitions and dividendsIncluding FMC dividends



Fresenius Group: Temporary headwinds driven by geopolitical turmoil and the COVID-19 pandemic weighing on FY/22 earnings growth

Headwinds for net income development FY/22e Reconciliation to new guidance



Material, supply chain and energy costs

Meaningful increases across all segments

Missing growth

 Staff shortages limit growth e.g. onboarding opportunities for new patients in dialysis clinics

Labor costs

 Headwinds primarily at FMC in the U.S. patient-facing service business

Offset

- Including monies from the U.S. government's Provider Relief Fund
- Compensating measures include tight cost control and product price increases wherever possible

Expectations H2/2022

- Neither meaningful worsening of macro challenges nor major COVID-19 pandemic effects leading to lock-downs factored in
- → Overall, we consider headwinds as temporary and not structural



Assumptions for Guidance FY/22

Special items are excluded.

The acquisitions of Ivenix and of the majority stake in mAbxience as well as any further potential acquisitions are excluded from guidance.

Fresenius expects significantly more pronounced headwinds from supply chain disruptions and cost inflation, including energy prices. Furthermore, significant negative effects from ongoing labor shortages and associated wage inflation, especially at Fresenius Medical Care in the U.S. are expected.

COVID-19 will continue to impact Fresenius Group operations in 2022; an unlikely but possible significant deterioration of the situation triggering containment measures that could have a significant and direct impact on the health care sector without any appropriate compensation is not reflected in the Group's FY/22 guidance.

The war in Ukraine is directly and indirectly affecting Fresenius Group operations. Fresenius will continue to closely monitor the potential further consequences of the war, including balance sheet valuations. The guidance does not consider a significant disruption of gas or electricity supplies in Europe.

FMC's updated guidance assumptions also apply to FSE guidance.



01 02 Financials & Outlook 04

FY/22 Financial Outlook by Business Segment

€m (exce	pt otherwise stated)		FY/21 Base	H1/22 prelim.	FY/22e	
SSS	FRESENIUS KABI	Sales growth (org)	7,193	1%	Low single-digit %	<u> </u>
		EBIT growth (cc)	1,153	-8%1	Decline in high single- to low double-digit %-range	<u> </u>
5	FRESENIUS HELIOS	Sales growth (org)	10,891	6%	Low-to-mid single-digit %	<u> </u>
		EBIT growth (cc)	1,127	7%	Mid single-digit %	<u> </u>
V	FRESENIUS VAMED	Sales growth (org)	2,297	4%	High single- to low double-digit %	<u> </u>
		EBIT	101	19	Returning to absolute pre-COVID levels (2019: €134 m)	<u> </u>

Before special items and including COVID-19 effects

For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.



¹ Excluding Ivenix acquistion

FY/22 Financial Guidance

€m (except otherwise stated)		FY/21 Base	H1/22	FY/22e	New
FRESENIUS	Sales growth (cc)	37,520	4%	Mid single-digit %	Low-to-mid single-digit %
	Net income growth (cc)	1,867	-3%1	Low single-digit %	Decline in low-to- mid single-digit %-range

Before special items and including COVID-19 effects Net income attributable to shareholders of Fresenius SE & Co. KGaA


For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.



¹ Excluding Ivenix acquisition

Agenda









Fresenius Kabi: Q2 & H1/22 Organic Sales Growth by Regions

Total sales	1,896	2%	3,743	1%
Emerging Markets	632	-2%	1,260	0%
Europe	658	4%	1,298	3%
North America	606	3%	1,185	0%
€m	Q2/22	Δ YoY organic	H1/22	Δ YoY organic

Fresenius Kabi: Q2 & H1/22 Organic Sales Growth by Product Segment

Total sales	1,896	2%	3,743	1%
Biosimilars	29	++	52	++
Infusion Therapy	245	10%	475	12%
Medical Devices/ Transfusion Technology	360	0%	717	0%
Clinical Nutrition	563	2%	1,117	3%
IV Drugs	699	-3%	1,382	-5%
€m	Q2/22	Δ YoY organic	H1/22	Δ YoY organic

Fresenius Kabi: Q2 & H1/22 EBIT Growth

€m	Q2/22	Δ YoY cc	H1/22	Δ YoY cc
North America	174	-4%	330	-10%
Margin	28.7%	-230 bps	27.8%	-330 bps
Europe	80	-17%	161	-26%
Margin	12.2%	-330 bps	12.4%	-480 bps
Emerging Markets	140	-18%	313	3%
Margin	22.2%	-380 bps	24.8%	+80 bps
Corporate and Corporate R&D	-123	0%	-240	13%
Total EBIT Margin	271 14.3%	-15% ¹ -270 bps	564 15.1%	-8% ¹ -120 bps

All figures before special items Margin growth at actual rates

¹ Excluding Ivenix acquistion

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.



Fresenius Helios: Q2 & H1/22 Key Financials

€m	Q2/22	Δ YoY cc	H1/22	Δ YoY cc
Total sales	2,925	5% ¹	5,856	6% ¹
Thereof Helios Germany	1,758	4%1	3,541	5%¹
Thereof Helios Spain	1,101	6%1	2,190	9%1
Thereof Helios Fertility	65		122	
Total EBIT Margin	303 10.4%	1% -50 bps	609 10.4%	7% -10 bps
Thereof Helios Germany Margin	154 8.8%	1% -30 bps	308 8.7%	2% -30 bps
Thereof Helios Spain Margin	148 13.4%	0% -100 bps	301 13.7%	10% +0 bps
Thereof Helios Fertility Margin	7 10.8%		11 9.0%	
Thereof Corporate	-6		-11	

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.



¹ Organic growth

All figures before special items

Fresenius Helios: Key Metrics

	H1/22	FY/21	Δ
Helios Germany			
Hospitals - Acute care hospitals	88 85	90 87	-2% -2%
Beds - Acute care hospitals	30,473 29,941	30,487 29,955	0% 0%
Admissions (acute care)	537,302	1,048,946	
Helios Spain			
Hospitals	58	56	4%
Beds	8,225	8,174	1%
Admissions (including outpatients)	9,598,613	17,122,592	

Fresenius Vamed: Q2 & H1/22 Key Financials

€m	Q2/22	Δ YoY cc	H1/22	Δ YoY cc
Total sales Thereof organic sales	562	1% 1%	1,075	3% 4%
Project business	145	-12%	253	-9%
Service business	417	6%	822	8%
Total EBIT ¹	11	-31%	19	58%
Order intake ²	253	-65%	516	-39%
Order backlog ²			3,732	7%3

Before special items
 Project business only
 Versus December 31, 2021

Fresenius Group: Q2/22 Key Financials

€m	Q2/22 ¹	special items	Q2/22 reported	Δ YoY cc ¹
Sales	10,018	-	10,018	3%
EBIT	1,003	-158	845	-9%
Net interest	-116	-	-116	10%
Income taxes	-204	39	-165	3%
Net income ²	450	-67	383	-9% ³

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.



¹ Before special items

 $^{^{\}rm 2}$ Net income attributable to shareholders of Fresenius SE & Co. KGaA $^{\rm 3}$ Before Ivenix acquisition

Fresenius Group: Calculation of Noncontrolling Interests

€m	H1/22	H1/21
Earnings before tax and noncontrolling interests	1,768	1,784
Taxes	-404	-395
Noncontrolling interests, thereof	-451	-478
Fresenius Medical Care net income not attributable to Fresenius (H1/22: \sim 68%)	-292	-321
Noncontrolling interest holders in Fresenius Medical Care	-112	-116
Noncontrolling interest holders in Fresenius Kabi (-€34 m), Fresenius Helios (-€9 m), Fresenius Vamed (-€2 m) and due to Fresenius Vamed's 23% external ownership (-€2 m)	-47	-41
Net income attributable to Fresenius SE & Co. KGaA	913	911

Before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.



Fresenius Group: Cash Flow

Q2/22	LTM Margin	Δ ΥοΥ
1,017	10.5%	-47%
-436	-4.9%	13%
581	5.6%	-73%
-271		
-701		
-391	1.6%	
	1,017 -436 581 -271 -701	1,017 10.5% -436 -4.9% 581 5.6% -271 -701

Fresenius Group: Estimated COVID-19 Effects Q2 & H1/22


	as rep	Growth cc as reported incl. COVID-19		nated impact cc	Estimated growth cc excl. COVID-19	
	Q2/22	Q2/21	Q2/22	Q2/21	Q2/22	Q2/21
Sales	3%	8%	1% to 0%	2% to 1%	2% to 3%	6% to 7%
Net income ¹	-10%	20%	6% to 2%	10% to 6%	-16% to -12%	10% to 14%

	Growth cc as reported incl. COVID-19			nated impact cc	Estimated growth cc excl. COVID-19		
	H1/22	H1/21	H1/22	H1/21	H1/22	H1/21	
Sales	4%	6%	0% to -1%	1% to 0%	4% to 5%	5% to 6%	
Net income ¹	-4%	8%	6% to 2%	4% to 0%	-10% to -6%	4% to 8%	

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA

Fresenius Group: Proven Track Record of Deleveraging

Net Debt/EBITDA¹



2002-2019 excluding IFRS 16


³ Including IFRS 16



¹ At actual FX rates from 2002 to 2010 and at average FX rates from 2011 onwards, for both Net Debt and EBITDA; before special items; pro forma closed acquisitions/divestitures

² Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG

Fresenius Group: Well-balanced maturity profile¹



 $^{^{1}}$ As of June 30, 2022, and based on utilization of major financing instruments, excl. Commercial Paper and A/R Facility 2 Calculations based on total financial debt, excluding Lease & Purchase Money Obligations




Fresenius Group: Sales by Business Segment – FX, Acquisitions/Divestitures Effects Q2/22

€m	Q2/22	Q2/21	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisi- tions	Divesti- tures/ Others
Fresenius Medical Care	4,757	4,320	10%	9%	1%	0%	1%	0%
Fresenius Kabi	1.896	1,755	8%	6%	2%	2%	0%	0%
Fresenius Helios	2,925	2,738	7%	1%	6%	5%	1%	0%
Fresenius Vamed	562	556	1%	0%	1%	1%	1%	-1%
Total	10,018	9,246	8%	5%	3%	2%	1%	0%



Fresenius Group: Solid Balance Sheet Structure



¹2019 including IFRS 16



Fresenius Group: Financial Performance Indicators

Profitability Growth Liqudity Capital efficiency Capital management Sales growth Operating cash flow **EBIT Operating income (EBIT)** Net debt +/ - Financial result ÷ EBITDA ÷ Sales Income taxes (in constant currency) Sales growth - Income taxes = Cash flow margin = NOPAT = Leverage ratio ÷ Invested capital (organic) - Minority interests = ROIC = Net income **EBIT EBIT** growth ÷ Operating assets (in constant currency) = ROOA **Net income growth** (in constant currency)



Fresenius Group¹: Performance Indicators 5-year Overview

	Targets 2021 ²	2021	2020	2019	2018	2017
Sales growth (in constant currency)	Mid single-digit %	5%	5%	6%	6%	16%
Net income ³ growth (in constant currency)	Around top-end of low single-digit %	5%	-3%	0%	7%	21%
Liquidity and capital management						
Cash flow margin	10% to 12%	13.5%	18.1%	12.0%/9.9%4	11.2%	11.6%
Net debt / EBITDA ⁵	Around the top-end of $3.0x - 3.5x^6$	3.51x	3.44x	3.61x/ 3.14x ⁴	2.71x	2.84x
Capital efficiency						
Return on invested capital (ROIC) ⁷	Decrease by 50 to 100 basis points compared to 2020 level	5.9%	6.5%	6.7% /7.4%4	8.3%	8.0%
Return on operating assets (ROOA) ⁷	Decrease by 40 to 70 basis points compared to 2020 level	6.5%	7.3%	7.6%/8.2%4	9.0%	9.4%

¹ Growth rates are based on the assumptions of the respective annual forecasts and are adjusted for special items and, if applicable, other effects affecting the underlying growth (adjustments to new accounting standards, acquisitions / divestments, acquisition costs, or cost-saving programs).

2 Including estimated COVID-19 effects (updated November 2021)

⁷ Before special items, pro forma acquisitions



³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

⁴ Excluding IFRS 16 effect

⁵ Both net debt and EBITDA calculated at LTM average exchange rates; before special items, pro forma closed acquisitions/divestitures

⁶ Around the top-end of the self-imposed target range of 3.0x to 3.5x; excluding further potential acquisitions

Business segments¹: Performance Indicators 5-year Overview

	Targets 2021 ²	2021	2020	2019	2018	2017
Fresenius Medical Care						
Sales growth (in constant currency)	Expecting to be at the lower end of the guidance range of low-to-mid single-digit %	2%	5%	5%	4%	9%
Net income growth ^{3,4} (in constant currency)	Expecting to be at the lower end of the guidance range of high-teens to mid-twenties %- decline	-23%	12%	-2%	4%	7%
Fresenius Kabi						
Sales growth (organic)	Low-to-mid single-digit %	4%	4%	4%	7%	7%
EBIT growth (in constant currency)	Around the top end of the low single-digit %-guidance range	7%	-6%	3%	2%	8%
Fresenius Helios						
Sales growth (organic)	Mid single-digit percentage growth	7%	4%	5%	3%	4%
EBIT growth (in constant currency)	High single-digit percentage growth	10%	0%	-4%	0%	54%
Fresenius Vamed						
Sales growth (organic)	Mid-to-high single-digit %	11%	-8%	16%	16%	6%
EBIT growth (in constant currency)	High double-digit € million amount	€101 million	€29 million	19%	45%	10%

¹ Growth rates are based on the assumptions of the respective annual forecasts and are adjusted for special items and, if applicable,

other effects affecting the underlying growth (adjustments to new accounting standards, acquisitions / divestments, acquisition costs, or cost-saving programs).

² Including estimated COVID-19 effects (updated November 2021)

³ Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

⁴ Special items are effects (when consolidated at the Fresenius Group: special items), that are unusual in nature and were not foreseeable or not foreseeable in size or impact at the time of giving guidance.

Financial Calendar / Contact





01 November 2022

Results Q3/22

Please note that these dates could be subject to change.



Contact

Investor Relations & Sustainability

Fresenius SE & Co. KGaA

phone: +49 6172 608-2485 e-mail: ir-fre@fresenius.com

For further information and current news: www.fresenius.com



www.twitter.com/fresenius ir



www.linkedin.com/company/fresenius-investor-relations